Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26–52, including a treatment switch from reference ADL to PF-06410293

Roy M Fleischmann,Ivana Vranic,Carol Cronenberger,Wuyan Zhang,Daniel F Alvarez,Rieke Alten,Amy E Bock

doi:10.1136/rmdopen-2021-001578

Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26–52, including a treatment switch from reference ADL to PF-06410293

Roy M Fleischmann, Ivana Vranic + Show 5 more

Open Access

https://doi.org/10.1136/rmdopen-2021-001578

Copy DOI

Journal: RMD Open	Publication Date: Apr 1, 2021
Citations: 10	License type: open-access

Affiliation: Metroplex Clinical Research Center, The University of Texas Southwestern Medical Center, Southwestern Medical Center, Pfizer (United Kingdom), Pfizer (United States), Schlosspark-Klinik

#Treatment Of Active Rheumatoid Arthritis #EULAR Good Response + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

ObjectiveTo investigate the efficacy, safety, immunogenicity and pharmacokinetics of biosimilar adalimumab (ADL) PF-06410293 (ADL-PF; adalimumab-afzb) versus EU-sourced reference ADL (ADL-EU) in patients with active rheumatoid arthritis (RA) on longer-term treatment...

Full Text